Established Use With Industry-Leading Partners
Epiontis ID has been used in phase 1 to phase 3 studies by some of the most prominent biopharmaceutical companies around the world. Explore the work our Epiontis team has conducted with these industry leaders.
Selection of Recent Publications
-
Epigenetic immune cell counting in human blood samples for immunodiagnostics.
Science Translational Medicine
Baron U, Werner J, Schildknecht K, et al. Epigenetic immune cell counting in human blood samples for immunodiagnostics. Sci Transl Med. 2018;10(452):eaan3508. doi: 10.1126/scitranslmed.aan3508. -
Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis.
Rheumatology (Oxford)
Burska AN, Thu A, Parmar R, et al. Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. Rheumatology (Oxford). 2019;58(11):2015-2024. doi: 10.1093/rheumatology/kez162. -
Epigenetically quantified immune cells in salivary glands of Sjögren’s syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology.
Rheumatology (Oxford)
Blokland SLM, van Vliet-Moret FM, Hillen MR, et al. Epigenetically quantified immune cells in salivary glands of Sjögren’s syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology. Rheumatology (Oxford). 2020;59(2):335-343. doi: 10.1093/rheumatology/kez268. -
Treatment with rapamycin can restore regulatory T-cell function in IPEX patients.
Journal of Allergy and Clinical Immunology
Passerini L, Barzaghi F, Curto R, et al.Treatment with rapamycin can restore regulatory T-cell function in IPEX patients. J Allergy Clin Immunol. 2020;145(4):1262-1271.e13. doi:10.1016/j.jaci.2019.11.043. Epub 2019 Dec 23. -
Circulating immune cell composition and cancer risk: a prospective study using epigenetic cell count measures.
Cancer Research
Le Cornet C, Schildknecht K, Rossello Chornet A, et al. Circulating immune cell composition and cancer risk: a prospective study using epigenetic cell count measures. Cancer Res. 2020;80(9):1885-1892. doi: 10.1158/0008-5472.CAN-19-3178. Epub 2020 Feb 19. -
Human LAP+GARP+FOXP3+ regulatory T cells attenuate xenogeneic graft versus host disease.
Theranostics
Wang H, Song H, Pham AV, et al. Human LAP+GARP+FOXP3+ regulatory T cells attenuate xenogeneic graft versus host disease. Theranostics. 2019;9(8):2315-2324. doi: 10.7150/thno.30254.